Danielle Seidman
Hematology & Oncology · New York, NYNPI 1285029710
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Gilead at 38.0% of the total. Reporting peaked in 2022 at $869 and has fallen 85.1% since, to $129 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 40 payments — averaging $43.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$654
- Novartis$262
- Seagen Inc.$194
- Merck$172
- Daiichi Sankyo Inc.$167
- Takeda Pharmaceuticals U.S.A., Inc.$82
- plus $188 from 5 others
What the payments were for
- Consulting fees$64037%
- Food & beverage$92454%
- Education$1569%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 3 | $654 |
| Novartis | 13 | $262 |
| Seagen Inc. | 4 | $194 |
| Merck | 7 | $172 |
| Daiichi Sankyo Inc. | 2 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
| Johnson & Johnson | 2 | $60 |
| Eisai Inc. | 2 | $46 |
| AstraZeneca | 2 | $44 |
| Stemline Therapeutics Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$143
How this compares
$1,720 in reported general payments places this provider in the 50th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 11 | $155,753 |
| Exemestane | 50 | $6,458 |
| Anastrozole | 247 | $5,174 |
| Letrozole | 63 | $1,321 |
| Tamoxifen Citrate | 48 | $705 |
| Lidocaine | 13 | $398 |
| Gabapentin | 23 | $136 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.